Aptiv, CGI Enter Clinical Service Alliance

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership to provide comprehensive solutions for the conduct of oncology clinical trials. Aptiv’s services include adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, and global operational support. CGI provides disease-specific biomarker knowledge, molecular testing and oncology lab services for the early stages of clinical trials.

The goal of the alliance is to provide clients with a better understanding of modes of action of a variety of therapeutics and the role for biomarkers in the oncology drug development process. Using genomic technologies and other methodologies, the alliance aims to provide early insight in complex diseases to help drive informed decisions and the successful development of targeted therapies.

“We are excited about partnering with CGI to enhance our ability to offer molecular and genetic laboratory expertise to our clients,” said Gene Resnick, MD, chief medical officer for Aptiv Solutions. “We recognize the critical role of biomarkers in the development of new agents in oncology and other therapeutic areas, and look forward to bringing a combined solution to the pharmaceutical, biotech and medical device industries which will enable clients to accelerate the progress of more efficient clinical trials. Adding this capacity to our existing expertise in oncology trial management will bring a value-add for sponsors and ultimately for patients.”

“Integrated clinical information is critical to providing customized patient treatment in which drug usage and dosage can be specifically targeted to the individual patient’s genetic requirement,” said Panna Sharma, chief executive officer of CGI. “As a leader in personalized medicine, CGI is confident that this collaboration will assist our clients in the development of new therapeutics and diagnostics by reducing the timeframe and costs for regulatory approval through patient stratification.”